Press release - February 23rd, 2012
Cerbomed at the 51st annual conference of the German Society for Epileptology
ERLANGEN/STUTTGART, Germany, February 23rd, 2012 – Between February 29th and March 3rd, 2012 cerbomed GmbH will introduce the transcutaneous Vagus Nerve Stimulation (t-VNS) with NEMOS at the 51st annual conference of the German Society for Epileptology in Stuttgart.
Participants will get the opportunity to inform themselves about the new therapy option at the booth and in the course of a symposium on March 1st.
Transcutaneous Vagus Nerve Stimulation is addressed to patients suffering from various difficult to treat neurological and psychiatric diseases. The t-VNS therapy uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses.
For t-VNS cerbomed developed and patented a special stimulator and a dedicated ear electrode. The stimulator, which is connected with the ear electrode, sends out the electrical impulses. With the transcutaneous vagus nerve stimulator NEMOS a targeted stimulation of the vagus nerve gets possible without the need of a surgery.
The German market entry for NEMOS is planned for the third quarter of 2012. NEMOS will then be available for patients suffering from hard-to-treat epilepsies and depressions.
Cerbomed GmbH is an innovative medical device company that concentrates on researching, developing and producing new technologies and products for neuromodulation. The company’s focus is on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard to treat neurological and psychiatric illnesses.
In March 2010 cerbomed received the European clearance (CE mark) for the transcutaneous vagus nerve stimulator NEMOS. In early 2012 two clinical studies will be starting regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine.